Study: CBD Reduces Inflammatory Pain While Improving Anxiety, Depression and Cognitive Symptoms
- CBD was found to reduce both acute and chronic inflammatory pain in mouse models, particularly attenuating inflammatory sensitization during the later phase of acute orofacial pain.
- CBD exerted its effects through multiple pathways, lowering pro-inflammatory markers and oxidative stress at inflammation sites via CB2 receptor activation, while modulating pain processing in the brain through CB1 receptor signaling.
- In chronic inflammatory pain models, systemic CBD improved pain-related emotional and cognitive dysfunctions, including anxiety-like behavior, depression-like behavior, and working memory deficits.
- CBD also restored serotonin signaling in the central amygdala, normalizing deficits linked to emotional processing, supporting its potential as a multi-dimensional treatment for both pain and associated emotional burdens.
A study published today by the journal Brain Research Bulletin found that CBD can help treat not only inflammatory pain, but also some of the anxiety, depression, and cognitive symptoms that can come with chronic pain. The research was conducted by scientists from the Academy of Military Medical Sciences and HaiDian District Maternal and Child Health Care Hospital in Beijing, China. Using multiple mouse models, researchers examined how CBD affected acute orofacial inflammatory pain, chronic inflammatory pain, and several behavioral changes linked to long-term pain.
In one part of the study, researchers used a formalin-induced model of acute orofacial pain and found that local CBD administration significantly reduced pain-related face-rubbing behavior, particularly during the inflammatory phase rather than the immediate acute phase. The study says CBD “significantly suppressed formalin-induced acute orofacial pain, specifically attenuating Phase II inflammatory sensitization.”
Researchers found that CBD appeared to work through several pathways. At the site of inflammation, it reduced pro-inflammatory markers including IL-1β and TNF-α, lowered PGE2, improved oxidative stress markers, and increased endocannabinoid activity. The findings indicate these peripheral effects were driven primarily through CB2 receptor activation. In the brain, CBD also reduced neuronal activation in regions involved in pain processing and increased anandamide in key pain-related areas, with those effects linked to CB1 receptor signaling.
The study also looked at chronic inflammatory pain using a separate mouse model. In that part of the research, systemic CBD reduced mechanical allodynia and improved multiple measures tied to pain-related emotional and cognitive dysfunction. Mice given CBD showed improvements in tests related to anxiety-like behavior, depression-like behavior and working memory.
Researchers also found that CBD restored serotonin-related signaling in the central amygdala, an area involved in emotional processing. According to the study, fiber photometry data showed CBD “normalized deficits in serotonin transient activity in the central amygdala.”
The researchers concluded that CBD “exerts robust multi-dimensional therapeutic effects across sensory, affective, and cognitive domains in inflammatory pain models,” adding that the findings support its potential as a treatment for both orofacial pain and the emotional burdens that often come with chronic pain.